
Please try another search
PRISM BioLab Co.,LTD, a biotechnology company, discovers and develops small molecule inhibitors of protein-protein interaction targets utilizing proprietary PepMetics technology for treating patients suffering from cancer, autoimmune, fibrosis, and other diseases. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company has license agreements with Eisai Co., Ltd. and Ohara Pharmaceuticals Co.,Ltd. for the development of drugs for treating cancer and liver diseases. PRISM BioLab Co.,LTD was founded in 2006 and is based in Fujisawa, Japan.
Name | Age | Since | Title |
---|---|---|---|
Shi Yin Foo | - | - | Member of Scientific Advisory Board |
Dai Takehara | 61 | - | Chairman, President & CEO |
Dean Rigel | - | - | Member of Scientific Advisory Board |
Hiromi Furushima | 54 | 2022 | Independent Outside Director |
Hiroshi Nagabukuro | - | - | Member of Scientific Advisory Board |
Yuji Ishiguro | 68 | 2022 | Chairperson of Audit & Supervisory Board |
Toshinobu Mamiya | 65 | 2023 | Outside Audit & Supervisory Board Member |
Teruhisa Tajima | 54 | 2018 | Outside Audit & Supervisory Board Member |
Kiichiro Kawada | 65 | 2021 | Outside Audit & Supervisory Board Member |
Hyi-Man Park | 56 | 2022 | Director of Research & Development Department and & Director |
Shinji Takeuchi | 62 | - | Director of Administrative Department & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review